UCB BIOPHARMA SRL

Parkinson's disease market to grow at 5.8% CAGR (2020-2034) due to advancements in diagnostics, increased awareness, and a rising number of cases. Emerging therapies like Supernus/Britannia's SPN-830, AbbVie's tavapadon, and Pharma Two B's P2B001 could significantly impact market dynamics. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size (2020-2034) for 7MM.

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.